EDT
vs
S
S&P TSX Composite Index (Canada)
EDT
Over the past 12 months, EDT has significantly outperformed S&P TSX Composite Index (Canada), delivering a return of +96% compared to the S&P TSX Composite Index (Canada)'s +27% growth.
Stocks Performance
EDT vs S&P TSX Composite Index (Canada)
Performance Gap
EDT vs S&P TSX Composite Index (Canada)
Performance By Year
EDT vs S&P TSX Composite Index (Canada)
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Spectral Medical Inc
Glance View
Spectral Medical, Inc. engages in the development and commercialization of therapeutic treatment for septic shock. The company is headquartered in Toronto, Ontario and currently employs 31 full-time employees. The firm has conducted a Phase III clinical trial for its lead product, PMX (Toraymyxin PMX-20R), which is for the treatment of patients with septic shock and endotoxemia that is measured by the Company’s Endotoxin Activity Assay (EAA). EAA and PMX are both Health Canada licensed and commercially available in Canada. The firm through its wholly owned subsidiary, Dialco Medical Inc., is also commercializing a new set of platforms addressing renal replacement therapy (RRT) across the dialysis spectrum. SAMI is targeting the acute RRT market, while DIMI is targeting the chronic RRT market.
